HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION

Clinical trials for HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION explained in plain language.

Never miss a new study

Get alerted when new HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION trials appear

Sign up with your email to follow new studies for HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Scientists test 'Goldilocks' drug dose to make transplants safer

Disease control Completed

This study tested whether a personalized dose of a drug called ATG works better than a standard fixed dose for patients receiving a stem cell transplant from a half-matched donor. The goal was to find the dose that best prevents a dangerous complication where the donor cells atta…

Matched conditions: HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION

Phase: PHASE3 • Sponsor: Chinese PLA General Hospital • Aim: Disease control

Last updated Apr 01, 2026 14:42 UTC

HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION

Get alerted when new HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION trials appear

Scientists test 'Goldilocks' drug dose to make transplants safer